OSE Immunotherapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Nantes France (2012)

Organization Overview

First Clinical Trial
2015
NCT02800811
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

OSE Immunotherapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 15